$2.06 Billion is the total value of NEA Management Company, LLC's 35 reported holdings in Q4 2014. The portfolio turnover from Q3 2014 to Q4 2014 was 17.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TSRO | TESARO INC | $366,480,000 | +38.1% | 9,854,255 | 0.0% | 17.77% | +31.8% | |
| GRPN | Sell | GROUPON INC | $364,869,000 | +0.5% | 44,172,953 | -18.7% | 17.69% | -4.1% |
| OPWR | OPOWER INC | $128,031,000 | -24.5% | 8,997,290 | 0.0% | 6.21% | -28.0% | |
| CLVS | CLOVIS ONCOLOGY INC | $127,668,000 | +23.5% | 2,279,781 | 0.0% | 6.19% | +17.8% | |
| RNA | PROSENSA HLDG NV | $121,503,000 | +122.4% | 6,480,171 | 0.0% | 5.89% | +112.1% | |
| ARDX | Sell | ARDELYX INC | $106,184,000 | +12.9% | 5,621,199 | -15.1% | 5.15% | +7.7% |
| EPZM | EPIZYME INC | $97,176,000 | -30.4% | 5,149,740 | 0.0% | 4.71% | -33.6% | |
| SUPN | SUPERNUS PHARMACEUTICALS INC | $88,395,000 | -4.5% | 10,650,000 | 0.0% | 4.29% | -8.9% | |
| CVT | Sell | CVENT INC | $83,429,000 | -34.2% | 2,996,738 | -40.0% | 4.04% | -37.2% |
| GLYC | GLYCOMIMETICS INC | $61,741,000 | +3.7% | 8,575,135 | 0.0% | 2.99% | -1.0% | |
| HPTX | HYPERION THERAPEUTICS INC | $57,221,000 | -4.8% | 2,384,221 | 0.0% | 2.78% | -9.2% | |
| NVRO | New | NEVRO CORP | $52,974,000 | – | 1,369,899 | +100.0% | 2.57% | – |
| TRIV | TRIVASCULAR TECHNOLOGIES INC | $49,591,000 | -13.2% | 3,945,191 | 0.0% | 2.40% | -17.2% | |
| FOLD | AMICUS THERAPEUTICS INC | $47,033,000 | +39.8% | 5,653,029 | 0.0% | 2.28% | +33.4% | |
| VTAE | VITAE PHARMACEUTICALS INC | $43,484,000 | +118.1% | 2,613,199 | 0.0% | 2.11% | +108.1% | |
| TRVN | Buy | TREVENA INC | $28,774,000 | +17.6% | 4,811,691 | +26.2% | 1.40% | +12.1% |
| CRCM | CARE COM INC | $27,001,000 | +1.6% | 3,260,989 | 0.0% | 1.31% | -3.1% | |
| WIFI | Sell | BOINGO WIRELESS INC | $26,534,000 | -16.7% | 3,459,460 | -22.6% | 1.29% | -20.5% |
| HIVE | AEROHIVE NETWORKS INC | $23,335,000 | -40.1% | 4,861,455 | 0.0% | 1.13% | -42.9% | |
| OREX | OREXIGEN THERAPEUTICS INC | $22,477,000 | +42.3% | 3,709,000 | 0.0% | 1.09% | +35.7% | |
| LOXO | New | LOXO ONCOLOGY INC | $21,058,000 | – | 1,792,207 | +100.0% | 1.02% | – |
| LXRX | Buy | LEXICON PHARMACEUTICALS INC | $15,175,000 | -7.8% | 16,676,000 | +42.8% | 0.74% | -12.1% |
| ROKA | ROKA BIOSCIENCE INC | $14,202,000 | -56.1% | 3,220,433 | 0.0% | 0.69% | -58.1% | |
| MM | MILLENNIAL MEDIA INC | $13,160,000 | -14.0% | 8,224,752 | 0.0% | 0.64% | -18.0% | |
| ECOM | CHANNELADVISOR CORP | $12,013,000 | +31.6% | 556,692 | 0.0% | 0.58% | +25.4% | |
| TRGT | TARGACEPT INC | $12,010,000 | +3.9% | 4,566,666 | 0.0% | 0.58% | -0.9% | |
| SNSS | SUNESIS PHARMACEUTICALS INC | $11,881,000 | -64.3% | 4,659,333 | 0.0% | 0.58% | -65.9% | |
| AUPH | AURINIA PHARMACEUTICALS INC | $9,271,000 | +13.8% | 2,546,843 | 0.0% | 0.45% | +8.7% | |
| ZHNE | ZHONE TECHNOLOGIES INC | $8,463,000 | -34.4% | 4,781,290 | 0.0% | 0.41% | -37.5% | |
| RIGL | RIGEL PHARMACEUTICALS INC | $7,362,000 | +17.0% | 3,243,150 | 0.0% | 0.36% | +11.6% | |
| PRTK | New | PARATEK PHARMACEUTICALS INC | $6,704,000 | – | 173,894 | +100.0% | 0.32% | – |
| EXEL | EXELIXIS INC | $3,178,000 | -5.9% | 2,207,000 | 0.0% | 0.15% | -10.5% | |
| ARQL | ARQULE INC | $3,075,000 | +8.9% | 2,520,316 | 0.0% | 0.15% | +4.2% | |
| AGRX | Buy | AGILE THERAPEUTICS INC | $802,000 | +267.9% | 130,644 | +337.7% | 0.04% | +254.5% |
| NURO | NEUROMETRIX INC | $112,000 | +8.7% | 57,273 | 0.0% | 0.01% | 0.0% | |
| TSPT | Exit | TRANSCEPT PHARMACEUTICALS INC | $0 | – | -2,086,755 | -100.0% | -0.22% | – |
| Exit | ALIMERA SCIENCES INC | $0 | – | -2,255,639 | -100.0% | -0.62% | – | |
| NKTR | Exit | NEKTAR THERAPEUTICS | $0 | – | -1,825,600 | -100.0% | -1.12% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-01-26
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| GLYCOMIMETICS INC | 39 | Q3 2023 | 7.6% |
| AURINIA PHARMACEUTICALS INC | 37 | Q3 2023 | 5.0% |
| CHAMPIONS ONCOLOGY INC | 33 | Q3 2023 | 1.2% |
| LEXICON PHARMACEUTICALS INC | 32 | Q3 2023 | 2.0% |
| ADAPTIMMUNE THERAPEUTICS PLC | 31 | Q3 2023 | 9.3% |
| TREVENA INC | 31 | Q3 2021 | 3.3% |
| AKARI THERAPEUTICS PLC | 31 | Q2 2023 | 0.3% |
| ARDELYX INC | 29 | Q3 2021 | 11.9% |
| RIGEL PHARMACEUTICALS INC | 29 | Q2 2020 | 0.6% |
| EPIZYME INC | 28 | Q1 2020 | 9.6% |
View NEA Management Company, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-10 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| 13F-HR | 2021-11-12 |
View NEA Management Company, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.